Member Info for Energyshares

Agree they are not presenting,but there is nothing stopping them negotiating a deal in one of the many negotiating rooms set up at this conference.

This conference is about deals that’s why JP Morgan sponsor it.

Chill & Relax read last RNS again:

“accelerate ongoing discussions“

"These emerging data give us, for the first time, the opportunity to accelerate ongoing discussions as well as to generate new opportunities through our business development activities aimed at delivering licensing opportunities for the pre|CISIONTM and Affimer® platforms."

Sit tight it’s happening

GLA

Cj

https://avacta.com/license-agreement-with-point-biopharma-inc/

Eli Lilly with a MCap of $556 billion now owns a licence to the Pre/Cision platform.

They have probably seen more data than any other BP because Point made it clear they were waiting for P1a data for Can Seek.

This could accelerate others to make a move.

GLA

AS has history attending the JP Morgan conference,in 2018 he was discussing deals (see link below)and then actually signed a deal at the JP Morgan conference in 2020 with Daewoong to form Affyxell.

Let’s hope a Pre/Cision deal can be signed there this year.

J.P. Morgan conferences bring together corporate leaders, financial sponsors and institutional investors to explore market and sector trends. J.P. Morgan conferences are by invitation only. Invitations are non-transferable.

2018

https://avacta.com/agm-business-update-and-notice-results-0/

I presented the Affimer technology and our recent progress at the JP Morgan conference in San Francisco last week.  We met with over twenty five biotech and pharmaceutical companies to discuss the benefits of the Affimer technology and potential partnerships.  Some of these have already followed up indicating their interest in further discussions.

2020

https://avacta.com/avacta-and-daewoong-agree-collaboration-and-license-agreement-with-affyxell-therapeutics/

 “As announced at the J.P. Morgan Healthcare Conference this January, Daewoong has been inspired to partner global biotechnology companies like Avacta to create the best and the most comprehensive technology in new drug development field.

Q&A release certainly puts TW and his troll team back in the gutter.

Every little bit of Fud they have attempted to discredit Avacta have been dealt with in these Answers,

Funding answered ✅

Licence agreements ✅

Cardio Toxcity ✅

Biopsies. ✅

ADC’s competition ✅

Fortnightly study ✅

FDA discussion’s ✅

Patents ✅

Timescale to market ✅

Manufacturing ✅

CAF’s TME ✅

Peer review ✅

Number of patients P2 ✅

Regulatory strategy ✅

Cmax ✅

Now can the Trolls STFU and move to another share and leave Avacta to complete its paradigm shift in oncology and help cancer patients in the future.

GLA

She is now listed Fiona M.

Just checked my LinkedIn and they are all still showing AS FMc EF SC

Just search Avacta then people

Having a bit of chill time I like to research Avacta and confirm to myself,I have stumbled across one of the rare unicorn shares that is fast growing, disruptive and has large market opportunities.

The FDA issued a guidance for industry, “Rare Diseases: Considerations for the Development of Drugs and Biological Products.”

This was issued just 3 days ago,reading through it was like it was written for Avacta.

I’m convinced Avacta will receive market approval for AVA6000 in 2024 and all I have to do is sit and wait and enjoy the ride.

https://www.fda.gov/media/119757/download

Happy new year

GLA

When the RNS was released on 4th December stating Avacta will present a detailed review of the AVA6000 clinical trial's Phase 1a data.

I thought we would receive on the 13th December:

What they had seen after 1st patient was dosed.

Details of data why FDA granted ODD

Details of what Safety Data Monitoring Committee (SDMC) was seeing and their reasons for escalating the drug strength on each cohort.

Details of early trial patient progress.

Details from all UK trial sites and their observations and patient enrolment and plans for UK sites moving forward.

Details of what they showed

Doctors William Tap (MSK) and Lee Cranmer ( Fred Hutch) for them to put their names to the trial.

Reasons why they presented this data before cohort 7 had completed.

Plans for peer review after C7 has completed.

December 13th

We received info about 5 patients in the USA part of the trial.

Although this info given was very good news, my question is why present after C6 and not wait until C7 has completed.

Reasons

To appease PI’s ?

Dought it, All though comms has been good of late they wouldn’t present just for PI’s

FDA communication ?

They are in close contact with FDA and communication would already be ongoing

BP licence deal or T/O ?

This to me has to be the reason for the trial update.

Once New year starts we could wake up any day to a 07:00am wonder dot.

Two dates for everyone’s diary

JP Morgan Health care conference

January 8-11, 2024

AACR

April 5 - 10, 2024

San Diego

Merry Christmas everyone.

Also gives over 65’s and patients with serious conditions that can’t be treated with Dox for cardiac toxic reasons a fighting chance ….

I agree they usually invest in seed capital JT, but a quick search on google you find they do invest in public companies.

My point was Shaun Chilton has a relationship with a few VC’s he was brought in for a reason and his experience will be vital in any future negotiations.

Also AS has access to all the VC’s who have invested in the Affyxell start up.

Optionality in deals

Optionality in funding

Venture-capital firms are jumping into the stock market , buying up battered shares in publicly traded tech companies at a time when they are investing less in the startups that have long been their focus.13 Oct 2022

Venture capitalists are in the business of investing money in businesses - small businesses, mid-sized companies and global enterprises - any company that shows potential for significant growth over the short term.

What is Avacta’s plan B.

I would have thought licence deals or a buy out would have come after P1a data.

Are they in talks ?

Have they had offers ?

Something happened in the summer after seeing the emerging C5 data.

Days before C5 completed they appoint Shaun Chilton.

Shaun Chilton at Clinigen

Clinigen business model:

https://www.clinigengroup.com/media/1652/8clinigen_business-model.pdf

Generates cash for Group investment (venture capital-backed )

Utilises unlicensed medicines supply and distribution infrastructure

Provides visibility of R&D pipeline

Commonality of client with early access

Transfer of patients from clinical trials to early access

On-demand’ identifies target medicines to acquire and revitalise

On-demand’ access identifies higher demand opportunities to develop, licence and commercialise medicines

On-demand’ helps identify geographies to internationalise commercial products

So this is another route to market for AVA6000 if Shaun can raise funds and leverage his contacts in venture capital and transfer of patients from AVA6000 clinical trial to early access like Clinigen they don’t need BP cash just yet, this could lead to a much stronger position in negotiations.

Just guess work but if Avacta can raise funds through venture capital if needed and show the market they can take AVA6000 through P2 and approval we will all benefit from a higher T/O.

Alongside his role as the CEO of Clinigen, Shaun was Non-Executive Chairman of C7Health, a disruptive, venture capital-backed medical technology and services business

Shaun has a track record of developing successful senior management teams and managing growth businesses and is passionate about Clinigen's mission to deliver the 'Right Medicine to the Right Patient at the Right Time'

With 25 year’s experience in the global pharmaceutical industry, Shaun has held a number of senior strategic, commercial and operational roles in the pharmaceutical industry and related service sectors covering the breadth of the product lifecycle.

GLA

We are aware of an account on X that is impersonating our CEO, Alastair Smith. We have taken measures to have it removed but please be aware that anyone claiming to be Alastair Smith on X is not genuine.

NY

Todays drop orchastrated by MM’s new investors mugged for stop losses

AIM is a 💩pot

Avacta my only holding on the 💩pot

Can’t wait for nasdaq

PI’s getting frustrated with AS and his promises of SP inflection points that never materialise.

Could Avacta’s II’s also start to want some SP growth after 3 years with large sums invested.

Is it time for AS to step aside ?

Who could replace him on the Avacta board or do they bring in fresh blood.

Shaun Chilton could do a very good job or after today’s performance Dr. Coughlin ?

She has the experience and with the trial continuing in the USA a perfect executive to deal with the FDA.

Privately held CytoImmune Therapeutics, Inc. strengthens its team by appointing cell therapy veteran Christina Coughlin, M.D., Ph.D. as CEO

Dr. Coughlin joins CytoImmune from Rubius Therapeutics, Inc. where she served as the Chief Medical Officer and led the clinical development, translational medicine, and regulatory efforts in the allogeneic red cell therapy platform. Prior to Rubius, Dr. Coughlin was with Tmunity Therapeutics, Inc., where she served as Chief Medical Officer and was responsible for the preclinical and clinical development of autologous CAR-T and TCR-T cellular therapies. Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Chief Medical Officer at Immunocore, heading the development of the soluble TCR platform, and Oncology Asset Team Leader at Pfizer.

Avacta gave a big middle finger to British government and MHRA today after the way they have been treated over the last few years.

No mention of continued clinical trials in UK

2 week study recruitment in USA

Even the header of the RNS was changed to American version ALS-6000-101 Phase 1a Study Data

I wouldn’t be surprised if NASDAQ listing and de-listing from Wild West AIM was next.

Lots of new investors gained over the last few weeks and I wouldn’t be surprised if this SP decline was orchestrated to take out newbies with stop losses in place.

AS needs to give Vox a miss, every time he gives them an interview the SP tanks.

He should have had one of the main news channels lined up today for this fantastic news.

Come Avacta get some main stream media lined up.

Janet Munro is back

Novartis

Great news for patients.Congratulations to the Avacta team for the vision and execution. Best is still to come ….🤞

Thanks for tweet RAH

Well the company who has asked to see the data and cut off C7 after one cycle must be in a rush to do a deal.

Let’s hope it’s the first of many.